FDA panel backs gene therapy for rare form of blindness

Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.

The panel voted unanimously in favor of the treatment, Luxturna, which is designed to treat inherited retinal diseases caused by defects in a gene known as RPE65, which tells cells to produce an enzyme critical to normal vision.

Read the full article at: http://wixx.com/news/articles/2017/oct/12/fda-panel-votes-in-favor-of-sparks-blindness-gene-therapy/

Featured Posts
Recent Posts
Archive
Search By Tags

We target cellular aging by Telomerase Gene Induction and  Gene Delivery.

About Us

Shop

Contact Us

Follow us

  • Grey Instagram Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon

© Defytime 2020, all rights reserved.